On July 21, 2022 Eli Lilly and Company (NYSE: LLY) reported that it will announce its second-quarter 2022 financial results on Thursday, Aug. 4, 2022 (Press release, Eli Lilly, JUL 21, 2022, View Source [SID1234616847]). Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at View Source A replay will also be available on the website following the conference call.

On July 21, 2022 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, reported that it will report second quarter financial results on Thursday, August 4, 2022, after the U.S. financial markets close (Press release, Dynavax Technologies, JUL 21, 2022, View Source [SID1234616846]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dynavax will host a conference call and live audio webcast on Thursday, August 4, 2022, at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company’s website at View Source A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

On July 21, 2022 Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, reported that, as authorized by its stockholders, the Company is implementing a consolidation (reverse stock split) of its outstanding Common Shares on the basis of one (1) new Common Share for every ten (10) currently outstanding (Press release, Cellectar Biosciences, JUL 21, 2022, View Source [SID1234616845]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of July 22, 2022, the Company will have approximately 6.1 million shares outstanding. The number of authorized shares and the par value per share will remain unchanged.

The new Common Shares will be effective for trading purposes as of the commencement of trading on Friday, July 22, 2022, and will trade under CUSIP number 15117F807. The Company’s ticker symbol, CLRB, will remain unchanged. The Company has amended its Certificate of Incorporation to effect the stock consolidation.

Proportionate voting rights and other rights of common stockholders will not be affected by the reverse stock split, other than as a result of the cashing out of fractional shares. Stockholders who would otherwise hold a fractional share will receive a cash payment in lieu of the fractional share. The number of outstanding options and warrants will be adjusted accordingly. Please direct any questions you might have regarding the reverse split to your broker or the company’s stock transfer agent, American Stock Transfer & Trust Company, by calling (800) 937-5449 (domestic), or (718) 921-8317 (international).

On July 21, 2022 Bristol Myers Squibb NYSE (BMY) reported the first biopharma three-year exclusive collaboration with the premier African American Family Organization, Jack and Jill of America, Inc. to inspire more Black and African American individuals to join the biopharma industry to assist in creating more equity and better health outcomes for all patients through student engagement (Press release, Bristol-Myers Squibb, JUL 21, 2022, View Source [SID1234616844]). The strategic alliance is an extension of BMS’ Tomorrow’s Innovators Historically Black College (HBCU) initiative launched with the goal of creating a sustainable bridge of talent to the biopharma industry from the HBCU community and aligns with BMS’s inclusion and diversity health equity commitments to increase workforce representation by creating and sustaining a pipeline of diverse talent.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will commence at Jack and Jill’s bi-annual 45th National Convention "The Power of a Dream" from July 26-31 in Orlando, Fla., where BMS will be the exclusive biopharma sponsor. The 2022 National Convention will exemplify the power of dreaming and significance of helping children to dream by featuring an interactive legacy gallery of notable Jack and Jill of America alumni in entertainment, business, government, education, media, technology, and social justice, among other industries. BMS will be involved in several events during the convention, including the flagship Programming Luncheon, the Mothers "Closing the Gap: Health, Wealth, and Wellness Forums and Expo" centered around addressing health inequities in the healthcare system and improving healthcare support for communities of color, a virtual career fair and an in-person booth engagement.

"We are so excited to join forces with such a historically prestigious organization like Jack and Jill of America, Inc., to further both of our missions to empower the Black youth to go after their dreams. We hope those dreams include joining the biopharma industry for young Black students," said Shamika Williams, senior director of HBCU initiatives at Bristol Myers Squibb. "In the biopharma industry, there is an immediate need for more diverse representation as it informs the future of medical advancements and resources that directly affect and serve minority communities. We are thrilled to be poised to help bridge this equity gap along with other influential leaders in the space."

"This inaugural collaboration opens the doors for Black and African American youth to learn about opportunities in the biopharma industry," said Kornisha McGill Brown, national president of Jack and Jill of America, Inc. "More representation in the industry helps to drive innovation, which is critical now more than ever to fight inequality in our current health system and to help people and communities achieve better health equity."

On July 21, 2022 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, reported a new collaboration with Baylor College of Medicine to identify and translate cutting-edge research into potential therapies for patients with genetic diseases (Press release, BridgeBio, JUL 21, 2022, View Source [SID1234616843]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In these challenging times we believe it is more important than ever to be a stalwart partner to academic institutions working to serve patient populations big and small. We look forward to developing a close partnership with scientists at Baylor College of Medicine, which is known for its productive research engine, in the hope of translating innovations into meaningful medicines for patients with unmet medical needs," said Neil Kumar, Ph.D., BridgeBio founder and CEO.

Baylor College of Medicine’s unique approach to therapeutic development for genetic diseases and precision oncology integrates basic, translational and clinical sciences. Through this collaboration, BridgeBio will work with Baylor College of Medicine to identify and translate promising innovations into potential therapies for patients with genetically driven diseases.

"Together with BridgeBio’s drug development team, we are optimistic that our interdisciplinary team of scientists and physicians will be able to develop new therapeutics for patients in need and further our mission to identify and develop drugs for a wide variety of diseases," said Joseph Petrosino, Ph.D., chief scientific innovation officer and chair and professor of molecular virology & microbiology at Baylor.

A core part of BridgeBio’s efforts to help patients is the identification of new discoveries in academia. Through its academic collaborations, BridgeBio seeks to revolutionize the relationships between the drug development industry and biomedical researchers by moving away from one-off interactions in favor of engaging and creative partnerships. For a list of some of BridgeBio’s academic partners, please visit Our Partners page.